147 related articles for article (PubMed ID: 34935484)
21. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
22. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
23. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
24. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.
Peng W; Ye Y; Rabinovich BA; Liu C; Lou Y; Zhang M; Whittington M; Yang Y; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2010 Nov; 16(22):5458-68. PubMed ID: 20889916
[TBL] [Abstract][Full Text] [Related]
25. IL-17-CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment.
Wu L; Awaji M; Saxena S; Varney ML; Sharma B; Singh RK
Am J Pathol; 2020 Jan; 190(1):222-233. PubMed ID: 31654638
[TBL] [Abstract][Full Text] [Related]
26. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
27. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
28. Forced Expression of CXCL10 Prevents Liver Metastasis of Colon Carcinoma Cells by the Recruitment of Natural Killer Cells.
Kikuchi N; Ye J; Hirakawa J; Kawashima H
Biol Pharm Bull; 2019 Jan; 42(1):57-65. PubMed ID: 30381616
[TBL] [Abstract][Full Text] [Related]
29. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
Kiany S; Gordon N
Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
[TBL] [Abstract][Full Text] [Related]
30. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
[TBL] [Abstract][Full Text] [Related]
31. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
[TBL] [Abstract][Full Text] [Related]
33. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
34. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
35. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
36. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
Daher M; Basar R; Gokdemir E; Baran N; Uprety N; Nunez Cortes AK; Mendt M; Kerbauy LN; Banerjee PP; Shanley M; Imahashi N; Li L; Lim FLWI; Fathi M; Rezvan A; Mohanty V; Shen Y; Shaim H; Lu J; Ozcan G; Ensley E; Kaplan M; Nandivada V; Bdiwi M; Acharya S; Xi Y; Wan X; Mak D; Liu E; Jiang XR; Ang S; Muniz-Feliciano L; Li Y; Wang J; Kordasti S; Petrov N; Varadarajan N; Marin D; Brunetti L; Skinner RJ; Lyu S; Silva L; Turk R; Schubert MS; Rettig GR; McNeill MS; Kurgan G; Behlke MA; Li H; Fowlkes NW; Chen K; Konopleva M; Champlin RE; Shpall EJ; Rezvani K
Blood; 2021 Feb; 137(5):624-636. PubMed ID: 32902645
[TBL] [Abstract][Full Text] [Related]
37. An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model.
Lee J; Kang TH; Yoo W; Choi H; Jo S; Kong K; Lee SR; Kim SU; Kim JS; Cho D; Kim J; Kim JY; Kwon ES; Kim S
Cancer Immunol Res; 2019 Feb; 7(2):219-229. PubMed ID: 30514792
[TBL] [Abstract][Full Text] [Related]
38. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells.
Bonanni V; Antonangeli F; Santoni A; Bernardini G
J Immunother Cancer; 2019 Nov; 7(1):290. PubMed ID: 31699153
[TBL] [Abstract][Full Text] [Related]
39. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
40. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]